ArticlePloS one2018
Metformin and insulin treatment prevent placental telomere attrition in boys exposed to maternal diabetes.
Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 24 citations in OpenAlex.
- Correlation of telomere length between full and preterm neonates and their mothers.Experimental and therapeutic medicine · 2025Article
- Effect of Imeglimin on mitochondrial function in patients with type 2 diabetes mellitus: a prospective cohort study.Frontiers in endocrinology · 2025Article
- Telomere stabilization by metformin mitigates the progression of atherosclerosis via the AMPK-dependent p-PGC-1α pathway.Experimental & molecular medicine · 2024Article
- Involvement of Inheritance in Determining Telomere Length beyond Environmental and Lifestyle Factors.Aging and disease · 2023Review
- Can Antidiabetic Medications Affect Telomere Length in Patients with Type 2 Diabetes? A Mini-Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Longitudinal Association of Telomere Dynamics with Obesity and Metabolic Disorders in Young Children.Nutrients · 2022Article
- Metformin's Mechanisms in Attenuating Hallmarks of Aging and Age-Related Disease.Aging and disease · 2022Article
- Article
- Metformin in aging and aging-related diseases: clinical applications and relevant mechanisms.Theranostics · 2022Review
- Hyperglycemia First Detected in Pregnancy in South Africa: Facts, Gaps, and Opportunities.Frontiers in clinical diabetes and healthcare · 2022Review
- Metformin for Cardiovascular Protection, Inflammatory Bowel Disease, Osteoporosis, Periodontitis, Polycystic Ovarian Syndrome, Neurodegeneration, Cancer, Inflammation and Senescence: What Is Next?ACS pharmacology & translational science · 2021Review
- Symptoms of Prenatal Depression Associated with Shorter Telomeres in Female Placenta.International journal of molecular sciences · 2021Article
- Metformin: A Potential Candidate for Targeting Aging Mechanisms.Aging and disease · 2021Review
- Benefits of Metformin in Attenuating the Hallmarks of Aging.Cell metabolism · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
Abstract
Shortened leukocyte and placental telomeres associated with gestational diabetes mellitus (GDM) suggest this exposure triggers telomere attrition contributing to adverse outcomes. We applied high resolution Single Telomere Length Analysis (STELA) to placenta from GDM pregnancies with different treatment pathways to determine their effectiveness at preventing telomere attrition. Differences in telomere length between control (N = 69), GDM lifestyle intervention (n = 14) and GDM treated with metformin and/or insulin (n = 17) was tested by Analysis of Covariance (ANCOVA) followed by group comparisons using Fisher's least significant difference. For male placenta only, there were differences in mean telomere length (F(2,54) = 4.98, P = 0.01) and percentage of telomeres under 5 kb (F(2,54) = 4.65, P = 0.01). Telomeres were shorter in the GDM lifestyle intervention group compared to both controls (P = 0.02) and medically treated pregnancies (P = 0.003). There were more telomeres under 5 kb in the GDM lifestyle intervention group compared to the other two groups (P = 0.03 and P = 0.004). Although further work is necessary, we suggest that early adoption of targeted medical treatment of GDM pregnancies where the fetus is known to be male may be an effective strategy for ameliorating adverse outcomes for children.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.